throbber
Page 1
`
`S. Narasimha Murthy, Ph.D.
` UNITED STATES PATENT AND TRADEMARK OFFICE
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
` CASE NO. IPR2018-00168
` U.S. PATENT NO. 9,549,938
`
`FLATWING PHARMACEUTICALS, LLC
`AND MYLAN PHARMACEUTICALS, INC.
`
` PETITIONERS
`
`VERSUS
`
`ANACOR PHARMACEUTICALS, LLC PATENT OWNER
`**************************************************
` DEPOSITION OF
`S. NARASIMHA MURTHY, PH.D.
`**************************************************
` APPEARANCES NOTED HEREIN
`
` DATE: JANUARY 11, 2019
` PLACE: MAYO MALLETTE PLLC
` 2094 OLD TAYLOR ROAD, STE 200
` OXFORD, MISSISSIPPI
` TIME: 9:37 A.M.
`
`REPORTED BY: TODD J. DAVIS
` BCR, CSR #1406, RPR
`
`JOB NO. 153636
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`
`3
`
`45
`
`6
`
`78
`
`9
`10
`11
`12
`13
`14
`
`15
`
`16
`17
`18
`19
`
`20
`21
`22
`23
`24
`25
`
`Page 1
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 2
`
`S. Narasimha Murthy, Ph.D.
`
`APPEARANCES:
`
` PHILIP SEGREST, JR., ESQ.
` Husch Blackwell
` 120 South Riverside Plaza
` Chicago, Illinois 60606
`
` COUNSEL FOR FLATWING
` PHARMACEUTICALS, LLC
`
` JAD MILLS, ESQ.
` Wilson Sonsini Goodrich & Rosati
` 701 Fifth Avenue
` Seattle, Washington 98104
`
` COUNSEL FOR MYLAN
` PHARMACEUTICALS, INC.
`
` AARON MAURER, ESQ.
` ANTHONY SHEH, ESQ.
` Williams & Connolly
` 725 Twelfth Street, NW
` Washington, D.C. 20005
`
` COUNSEL FOR PATENT OWNER
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`
`34
`
`5
`
`678
`
`9
`10
`11
`
`12
`
`13
`14
`15
`
`16
`17
`18
`
`19
`
`20
`21
`22
`23
`
`24
`25
`
`Page 2
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`Page 3
`
`S. Narasimha Murthy, Ph.D.
` INDEX
` 1
`Style and Appearances .....................
` 3
`Index .....................................
` 4
`Examination by Mr. Sheh ...................
`Examination by Mr. Segrest ................ 71
`Further Examination by Mr. Sheh ........... 85
`Certificate of Court Reporter ............. 86
`Certificate of Deponent ................... 87
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 3
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 4
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` S. NARASIMHA MURTHY, Ph.D.,
`having been first duly sworn, was examined and
`testified under oath as follows:
`EXAMINATION BY MR. SHEH:
` Q. Good morning, Dr. Murthy.
` A. Good morning.
` Q. Would you please state your full name
`for the record?
` A. S. Narasimha Murthy. Sathyanarayana
`Narasimha Murthy.
` Q. Okay. Could you spell that for the
`court reporter?
` A. S-A-T-H-Y-A-N-A-R-A-Y-A-N-A. And middle
`name, N-A-R-A-S-I-M-H-A. Last name, Murthy,
`M-U-R-T-H-Y.
` Q. Okay. My name is Tony Sheh. I'm from
`Williams & Connolly. And with me today is Aaron
`Maurer. We're representing the patent owner,
`Anacor Pharmaceuticals, Inc.
` A. Okay.
` Q. Is it your understanding that you're
`testifying today as a witness on behalf of
`Flatwing Pharmaceuticals?
` A. Yes, I am.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 4
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 5
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` Q. And do you understand that you're
`testifying and for -- in your party's review
`proceedings pending before the patent trial and
`appeal board?
` A. Yes, I do.
` Q. And you understand Flatwing to be the
`petitioner in these proceedings?
` A. That's correct.
` Q. And you understand Anacor to be the
`patent owner?
` A. That's right.
` Q. Showing Exhibit 1048.
` MR. SEGREST: Are these just the
` patents?
` MR. SHEH: Yeah.
`BY MR. SHEH:
` Q. Dr. Murthy, do you recognize Exhibit
`1048?
` A. Yes, I do.
` Q. What is Exhibit 1048?
` A. It is my declaration.
` Q. Is that your reply declaration filed in
`all four of the inter partes review proceedings?
` A. That's correct.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 5
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 6
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` Q. Is it okay if I refer to Exhibit 1048 as
`your reply declaration?
` A. Yes.
` Q. And you filed this reply declaration
`in -- just going in case number -- first case
`number IPR 2018-00168; is that correct?
` A. Correct.
` MR. SEGREST: Object to form.
`BY MR. SHEH:
` Q. And IPR 2018-00168 involves U.S. Patent
`No. 9549938; is that correct?
` A. Can you come again? What was the patent
`number?
` Q. Yes. IPR -- does IPR 2018-00168 --
` A. Uh-huh (affirmative response).
` Q. -- involve or concern U.S. Patent
`No. 9549938?
` A. That's correct.
` Q. And the second IPR, is that IPR
`2018-00169?
` A. Right.
` Q. And does IPR 2018-00169 involve U.S.
`Patent No. 9566289?
` A. Correct.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 6
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 7
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` Q. And is the third IPR, IPR 2018-00170?
` A. Correct.
` Q. And does IPR 2018-00170 concern U.S.
`Patent No. 9566290?
` A. Correct.
` Q. And, finally, the fourth IPR, is that
`IPR 2018-00171?
` A. Yes, sir.
` Q. And does IPR 2008-00171 concern U.S.
`Patent No. 9572823?
` A. Correct.
` Q. And will you understand if I refer to
`the patents at issue by the last three digits of
`their patent number?
` A. Yes, sir.
` Q. Do you recall being previously deposed
`in this matter?
` A. Yes, sir. I recall.
` Q. Do you remember when that deposition
`was?
` A. I think sometime late August.
` Q. Okay. Was that August 2018?
` A. 2018. Correct.
` Q. And prior to your deposition in August
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 7
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 8
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`2018, did you file declarations in support of
`Flatwing's petition for inter partes review?
` A. Yes, I did.
` Q. Okay. And were those declarations
`subject of your August 2018 deposition?
` A. Come again, please.
` Q. Were those declarations the subject of
`your August 2018 deposition?
` A. Deposition. That's correct.
` Q. Did you review your deposition
`transcripts to prepare your reply declaration?
` A. I did review the deposition transcript.
` Q. To prepare -- did you review it to
`prepare for your reply declaration?
` A. Not to prepare. But I -- in general, I
`review my deposition transcripts just for my
`information.
` Q. Okay. So did you review your deposition
`transcripts prior to preparing or submitting your
`reply declaration?
` A. Yes, I did.
` Q. Okay. So I'm going to assume that --
`for today, that you're generally familiar with
`your previous deposition and declarations, but if
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 8
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 9
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`you don't understand a question, please let me
`know. Otherwise, I'll assume that you understand
`my questions.
` Is that all right?
` A. Come again?
` Q. I'm going to assume that you're familiar
`with the subject matter of your prior deposition
`in this case and your declarations, but if you
`don't understand a question, please me know.
` A. Okay.
` Q. Is that all right?
` A. Sure. Sure.
` Q. Were you also a witness on behalf of the
`Coalition of Affordable Drugs -- or Coalition for
`Affordable Drugs in three other inter partes
`review proceedings?
` A. I was.
` Q. And the Coalition for Affordable Drugs
`was the petitioner in those proceedings, correct?
` MR. SEGREST: Objection. Relevance.
` Scope.
` A. I was hired by March & Goff as an expert
`witness, yes. They wrote the petition.
` Q. Was that Merchant & Gould --
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 9
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 10
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` A. Merchant & Gould.
` Q. -- who retained you?
` A. That's right.
` Q. Okay. And were the patents involved in
`those other proceedings related to the four
`patents that are the subject of your reply
`declaration?
` MR. SEGREST: Same objection.
` A. That's correct.
`BY MR. SHEH:
` Q. Are you aware that another petitioner,
`Mylan Pharmaceuticals, has joined these
`proceedings since your August 2018 deposition?
` A. The question is again, please?
` Q. Are you aware that another petitioner,
`Mylan Pharmaceuticals, Inc., has joined these
`proceedings since your August 2018 deposition?
` A. Yes, I am.
` Q. Have you been retained by Mylan?
` A. No, I have not.
` Q. So you don't have a retainer agreement
`with Mylan?
` A. No, I don't.
` Q. And you don't have a confidentiality
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 10
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 11
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`agreement with Mylan?
` A. No, I don't.
` Q. Okay. When was the last time that you
`reviewed your reply declaration?
` A. Sometime, I believe, December 2018.
` Q. And after December 2018, you didn't look
`at your reply declaration?
` A. No.
` Q. What materials did you review in
`preparing your reply declaration?
` A. In preparing the reply declaration, I
`reviewed my -- I reviewed Dr. Lane's declaration.
`I reviewed Austin patent, Brehove patent, Freeman
`patent. That is all I can recall now.
` Q. Did you review Dr. Reider's declaration?
` A. Not -- at that time, I did not review
`Dr. Reider's declaration.
` Q. Have you reviewed Dr. Reider's
`declaration?
` A. I reviewed the -- I reviewed
`Dr. Reider's declaration just recently. That is
`correct. After submission of the declaration --
`my declaration.
` Q. So the first time that you -- was the
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 11
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 12
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`first time that you -- sorry. Strike that.
` Was the first time that you
`reviewed Dr. Reider's declaration after you
`submitted your reply declaration?
` A. Correct.
` Q. Did you review the patent owner's
`response?
` A. No. Not -- not prior to submission of
`the declaration.
` Q. Did you review -- did you review the
`patent owner's exhibits?
` A. No, sir, I didn't.
` Q. Did you review declarations from
`Dr. Kahl, including his reply declaration?
` A. I don't recall reviewing his
`declaration.
` Q. Are you familiar with Dr. Kahl?
` A. Yes. I know that he's one of the expert
`witness on this case.
` Q. Okay. Without disclosing any privileged
`information, can you tell me what you did to
`prepare for today's deposition?
` A. I reviewed my declaration. Again, I
`reviewed the patent claims, and I reviewed Austin,
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 12
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 13
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`Brehove, and Freeman patents. I also reviewed
`Dr. Reider's declaration, Dr. Lane's declaration,
`as well.
` Q. Okay. Was your review of Dr. Reider's
`declaration, in preparation for today's
`deposition, the first time that you reviewed
`Dr. Reider's declaration?
` A. That's right.
` Q. Sorry. Let's take a step back.
` In preparing your reply
`declaration, did you review Samour?
` A. I did review Samour.
` Q. Okay. Did you meet with counsel to
`prepare for your deposition today?
` A. Yes, I did.
` Q. Okay. How long did you meet with
`counsel?
` A. About five hours yesterday.
` Q. Okay. Did you review any documents or
`materials that haven't been cited in your reply
`declaration in preparation for your deposition
`today?
` A. Basically, we went over my declaration,
`and my counsel was trying to make me -- my
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 13
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 14
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`counsel --
` MR. SEGREST: I'm going to instruct you
` not to answer go into specifics of what we
` discussed.
` THE WITNESS: Okay.
` MR. SEGREST: He's asking if you -- I
` think the question was whether you reviewed
` any other materials.
`BY MR. SHEH:
` Q. Yes. Materials -- material or
`documents.
` A. No, I did not.
` Q. Okay. Showing what's been marked as
`Exhibit 1006.
` A. Okay.
` Q. Dr. Murthy, do you recognize Exhibit
`1006?
` A. Yes, I do.
` Q. Could you -- what is Exhibit 1006?
` A. It's my CV.
` Q. Okay. And this is the CV that you
`submitted in this case, correct?
` A. Right. That's correct.
` Q. Okay. Since your deposition in August
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 14
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 15
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`2018, has there been any updates to your CV?
` A. Not in this exhibit. I did not update
`the CV --
` Q. Right. I understand.
` A. -- submitted as an exhibit.
` Q. So my question, you keep copy of -- you
`keep a copy -- sorry. Strike that.
` You have a version of your
`curriculum vitae that up to date; is that right?
` A. That's correct. Yeah.
` Q. And my question is, are there any things
`on that CV, the one you keep current, that aren't
`reflected in Exhibit 1006?
` A. No.
` Q. So there have been no updates?
` A. No.
` Q. Okay. So there have been no updates to
`your CV since August 2018?
` A. On this -- this version. The exhibit
`version was not updated. It is the same version
`since I submitted.
` Q. Okay. Are there any differences between
`the version of your curriculum vitae that you keep
`current and Exhibit 1006?
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 15
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 16
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` A. Yes.
` Q. What differences are there -- strike
`that.
` What differences appeared after
`your deposition in August 2018?
` A. I updated my CV. But a few
`publications -- recent publications.
` Q. Were there any other updates besides
`publications?
` A. I probably included a couple of awards
`that I received on the CV.
` Q. Off the top of your head, were any of
`the publications that you added related to
`transungual or ungual penetration?
` A. I don't think was there -- there was
`anything that was transungual.
` Q. Were any of those publication -- did any
`of those publication that you added after August
`2018 relevant to onychomycosis?
` A. Can't recall any of the publications
`that I added related to onychomycosis.
` Q. Okay. So can't recall whether those
`publications were relevant to onychomycosis?
` A. Right. Most likely, I did not do any
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 16
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 17
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`work on onychomycosis in the past six months. So
`it's likely that I didn't have any publications.
` Q. I see.
` And with respect to the awards you
`mentioned, what awards were those?
` A. One of the awards was by American
`Association of Pharmaceutical Scientists. And the
`other -- a couple of grant awards from the
`granting agencies.
` Q. Were any of those grants related to
`transungual or ungual drug delivery?
` A. No.
` Q. Did any of those grants concern
`onychomycosis or treatments for onychomycosis?
` A. No.
` Q. Okay. In your experience and/or
`training, have you ever participated in any
`dose-ranging studies?
` MR. SEGREST: Object to the form.
` A. I want to know what you mean by
`participated in dose ranges study.
`BY MR. SHEH:
` Q. What do you think participated means or
`could mean?
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 17
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 18
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` A. I want to know what exactly you -- how
`do define participation in a dose range study,
`before I answer the question.
` Q. Right. I'm happy to use whatever
`meaning you choose. So I'm asking what your
`meaning -- or what meaning you would ascribe to
`the word "participate."
` A. I think I would need a clearer question,
`if you don't mind.
` Q. Okay.
` MR. SEGREST: So I think the confusion
` is participants can the people who are the
` subjects being studied, as opposed to the
` people who are conducting the study. So
` maybe you can clarify the question.
` MR. SHEH: Sure. I'm happy to. And
` thank you for that, Philip.
`BY MR. SHEH:
` Q. Have you ever participated in any
`dose-ranging studies as part of conducting the
`dose-ranging study?
` A. So, again, when you're asking me
`participating in a dose-ranging study, as the
`conductor of the study, would that mean that it is
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 18
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 19
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`a clinical study or a preclinical study?
` Q. Well, have you participated in any
`dose-ranging studies as part of a clinical trial?
` A. No.
` Q. Okay. Have you participated in any
`dose-ranging studies as part of clinical trials to
`obtain FDA approval of a new drug product?
` A. I did not.
` Q. Have you performed a dose-ranging study
`to assist you in arriving at your opinions in this
`case?
` A. Question, please?
` Q. Have you performed a dose-ranging study
`to assist you in arriving at your opinions in this
`case?
` A. I did not do any dose-ranging study on
`tavaborole.
` Q. What was that last word? I'm sorry?
` A. Tavaborole.
` Q. As a?
` A. As such on tavaborole.
` Q. I understand. Thank you.
` Did you perform any independent
`experiments or analytical measurements in
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 19
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 20
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`connection with your opinions in this case?
` A. Unders the --
` MR. SEGREST: Objection. Compound.
`BY MR. SHEH:
` Q. Did you perform any independent
`experts --
` A. Uh-huh (affirmative response).
` Q. -- in connection with forming your
`opinions in this case?
` A. I did not conduct any experiments to
`arrive at the conclusion.
` Q. Did you perform any analytical
`measurements in connection with forming your
`opinions in this case?
` A. I did not do any analytical measurements
`on tavaborole to arrive at conclusions in this
`case.
` Q. Okay. Have you opined in this case that
`dose-ranging studies are a routine part of the
`drug development process and well understood by
`those in -- those skilled in the art?
` A. Correct.
` Q. And have you opined in this case that
`dose-ranging studies are a part of the
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 20
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 21
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`standardized process for obtaining regulatory
`approval from the FDA?
` A. Correct.
` Q. So does the fact that dose-ranging
`studies are, quote, a routine part of the drug
`development process and part of the standardized
`process for obtaining regulatory approval from the
`FDA mean that the dose of any FDA approved drug is
`obvious because of the -- because of those facts?
`Strike that. I'll rephrase it.
` Does this mean that the dose of any
`FDA approved drug is obvious because it was
`arrived at through what you opine to be a routine
`and standardized process?
` MR. SEGREST: Objection. Calls for
` legal conclusion.
` A. Could you rephrase the question, please?
`BY MR. SHEH:
` Q. Sure.
` You opined that dose-ranging
`studies are routine, correct?
` A. That is correct.
` Q. That they're a routine part of the drug
`development process, correct?
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 21
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 22
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` A. That's right.
` Q. And you also opined that dose-ranging
`studies are part of the standardized process for
`obtaining regulatory approval from the FDA,
`correct?
` A. Correct.
` Q. So do those facts mean that the dose
`arrived for a drug product that is FDA approved is
`always obvious?
` MR. SEGREST: Same objection.
` A. I didn't understand the word "always
`obvious." What do you mean by that?
`BY MR. SHEH:
` Q. Do you opine that --
` A. Uh-huh (affirmative response).
` Q. You opined that the 5 percent
`limitation -- strike that.
` Do you understand -- will you -- do
`you understand -- sorry.
` Do you understand the claims of the
`patents at issue to recite a concentration of
`tavaborole at 5 percent weight by weight?
` A. Correct.
` Q. That's your understanding, correct?
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 22
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 23
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` A. That's correct.
` Q. That's a dose of tavaborole, correct?
` A. That is the strength of Kerydin
`formulation.
` Q. Right.
` And you've opined that that
`strength or concentration is obvious, correct?
` A. That is the strength at which Kerydin is
`approved by FDA.
` Q. Have you opined that the 5 percent
`concentration is obvious?
` A. 5 percent concentration is the strength
`of Kerydin that is approved by FDA.
` Q. In this case, have you at any point in
`time opined that the 5 percent concentration
`recited in the claims of the patents at issue is
`obvious?
` MR. SEGREST: Objection to form.
` A. Question again, please. I can't recall
`the question. Please come back again.
` (Question was read back.)
` MR. SEGREST: Objection to form.
` Relevance. And misstates the legal standard.
` A. 5 percent concentration is obvious in --
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 23
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 24
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`in the context that, you know, we generally test
`formulations of different concentrations of the
`drug. 5 percent is -- is inclusive of the
`concentration -- the dose range that we generally
`test the product when we are developing the
`product.
`BY MR. SHEH:
` Q. And that testing that you're referring
`to just now are the dose-ranging studies, correct?
` A. The dose-ranging studies, when you
`say -- are you again referring to the clinical
`trials? Do you mean it is clinical trials or...
` Q. I'm happy to take it as dose-ranging
`studies as part of a clinical trial.
` A. The dose-ranging studies as a part of
`the clinical trial is not required to arrive at an
`optimum concentration of drug in the formulation.
`That is only an FDA requirement for approval of
`the product.
` Q. And that testing or those dose-ranging
`studies are -- you opine to be routine, correct?
` A. That is correct.
` Q. And you opine that they're part of the
`standardized process for obtaining FDA approval,
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 24
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 25
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`correct?
` A. Dose-ranging studies is also a part of
`the FDA -- FDA process of approving the drug.
` Q. And so does that mean that the dose that
`is arrived at through those studies is obvious?
` MR. SEGREST: Objection. Relevance.
` Legal conclusion.
` A. Again, the question is not clear to me.
`So the dose-ranging studies that FDA requires
`would be run in a clinical setting. It's a human
`subject study. So to arrive at 5 percent strength
`in your formulation, there are other factors to be
`considered.
`BY MR. SHEH:
` Q. So are you distinguishing -- so those
`other factors are not being considered in the FDA
`dose-ranging study? Sorry. I'll strike that.
` Are the factors to which you refer
`not considered during the FDA dose-ranging
`studies?
` MR. SEGREST: Objection to form.
` A. I only know that dose-ranging studies
`are required when you want to get the product
`approved.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 25
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 26
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`BY MR. SHEH:
` Q. And does going through that process
`necessarily mean that the dose strength or
`concentration of the resulting drug product is
`obvious?
` MR. SEGREST: Same objection.
` A. Could you tell me how would that be
`obvious?
` MR. SHEH: Strike as nonresponsive.
`BY MR. SHEH:
` Q. There's a question pending. Do you know
`the answer to the question?
` A. No. The question is not clear to me.
` Q. Why isn't it clear to you?
` A. So you're asking me like, you know, when
`a new product need to be approved, the
`dose-ranging studies are performed, and you arrive
`at a dose that's good for human use. So that's
`what it is. I have no idea what you mean by is
`that dose obvious.
` Q. You have no idea what I mean when I'm
`asking whether the dose -- that word concentration
`or strength --
` A. Uh-huh (affirmative response).
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 26
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 27
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` Q. -- that's arrived at --
` A. Right.
` Q. -- at the end of that dose-ranging study
`is obvious? Is that what you don't understand?
` A. Yeah. I think it's -- that's part of --
`that part is not clear to me.
` Q. So you've opined on the question of
`obviousness in this case, correct?
` A. That's correct.
`BY MR. SHEH:
` Q. Okay.
` MR. SEGREST: Objection. Foundation.
` Go ahead.
`BY MR. SHEH:
` Q. You've opined in this case on the
`question of obviousness, correct?
` MR. SEGREST: Objection. Foundation.
` A. Correct.
` MR. SEGREST: Go ahead.
`BY MR. SHEH:
` Q. And my question is, does the facts -- in
`the same way that you opined in the meaning of
`obviousness, does the fact that a -- that a drug
`product goes through the FDA required dose-ranging
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 27
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 28
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`study mean that the dose or concentration would
`have been obvious?
` MR. SEGREST: Objection. Foundation.
` Relevance. Legal conclusion.
` A. I only opined that dose-ranging studies
`is a part of product approval process by FDA. I
`mean, that department...
`BY MR. SHEH:
` Q. So with respect to the FDA dose-ranging
`studies, your opinion -- sorry. Strike that.
` So with respect to the parts of
`your reply declaration that discuss FDA required
`dose-ranging studies, those opinions are limited
`to the fact that those dose-ranging studies are
`required?
` A. They are routine and required.
` Q. What do you mean by routine?
` A. Like you follow a standard protocol to
`do the studies.
` Q. What is the standard protocol?
` A. As per the FDA guidance.
` Q. Did you review any FDA guidance?
` A. No.
` Q. Have you ever reviewed an FDA guidance
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 28
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 29
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`for dose-ranging studies?
` A. Again, I think we are talking two
`different things here. I know that FDA requires a
`dose-ranging study to be performed before you
`submit a new drug application. So that doesn't
`require me to go over every details in the
`guidelines.
` MR. SHEH: Let's take a break.
` (A short recess was taken.)
`BY MR. SHEH:
` Q. In arriving at your opinions in this
`case, have you reviewed any FDA guidance?
` A. I'm generally aware of the guidelines.
`I'm -- I -- my experience, I review a lot of new
`drug application -- applications that are
`submitted to FDA. So I'm aware that dose-ranging
`studies is a requirement by FDA when you want to
`get that new drug application -- the new drug
`application approved.
` Q. Okay. You didn't cite any FDA guidance
`in your reply declaration, did you?
` A. I'm not sure if -- I did not cite those.
` Q. You did not cite those?
` A. No.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 29
`
`Anacor Exhibit 2046
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc.
`IPR2018-00168
`
`

`

`Page 30
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` Q. Okay. What form does the FDA supply its
`guidance in?
` A. What do you mean by what form?
` Q. How does the FDA supply guidance?
` A. Not -- not a fair question.
` Q. You don't understand what the -- how the
`FDA supplies guidance?
` MR. SEGREST: Objection.
` Mischaracterizes his testimony.
` A. FDA guidelines are available on the --
`on the website.
`BY MR. SHEH:
` Q. Okay.
` A. That's all I know.
` Q. Did you review any of those guidelines
`on the we

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket